A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Tisotumab-vedotin (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Cervical cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms innovaTV 204
- Sponsors Genmab; Seagen
Most Recent Events
- 30 Apr 2025 Results evaluating Molecular profiling of tisotumab vedotin-treated patients presented at the 116th Annual Meeting of the American Association for Cancer Research.
- 31 Mar 2025 According to a Genmab media release, announced today that the European Commission (EC) has granted marketing authorization for TIVDAK (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy based on this trial.
- 01 Sep 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record (2 Aug 2022).